Cargando…

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab

Adult-onset Still’s disease (AOSD) is a systemic auto-inflammatory disease characterized by the presence of immunologically mediated inflammation and deficient resolution of inflammation. Canakinumab is an approved IL-1β inhibitor in the treatment of AOSD with a balanced efficacy and safety profile....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghannam, Khetam, Zernicke, Jan, Kedor, Claudia, Listing, Joachim, Burmester, Gerd-R., Foell, Dirk, Feist, Eugen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509487/ https://www.ncbi.nlm.nih.gov/pubmed/34640417 http://dx.doi.org/10.3390/jcm10194400

Ejemplares similares

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
por: Kedor, Claudia, et al.
Publicado: (2020)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis
por: Ghannam, Khetam, et al.
Publicado: (2020)

A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis
por: Zernicke, Jan, et al.
Publicado: (2016)

Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
por: Kedor, Claudia, et al.
Publicado: (2021)

Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis
por: Ospelt, Caroline, et al.
Publicado: (2017)

Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients
por: ten Hagen, Alexander, et al.
Publicado: (2023)

Upregulation of Immunoproteasome Subunits in Myositis Indicates Active Inflammation with Involvement of Antigen Presenting Cells, CD8 T-Cells and IFNγ
por: Ghannam, Khetam, et al.
Publicado: (2014)

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
por: Galozzi, Paola, et al.
Publicado: (2018)

Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
por: Niccoli, Laura, et al.
Publicado: (2015)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease
por: Vitale, Antonio, et al.
Publicado: (2020)

Blockage of interleukin-1β with canakinumab in patients with Covid-19
por: Landi, Lorenza, et al.
Publicado: (2020)

Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity
por: Nirmala, Nanguneri, et al.
Publicado: (2015)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry
por: Vitale, Antonio, et al.
Publicado: (2022)

Adult-Onset Still’s Disease
por: Mitrovic, Stéphane, et al.
Publicado: (2019)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Canakinumab and mycophenolate mofetil in managing proteinuria/renal amyloidosis secondary to adult-onset Still’s disease
por: Feng, Jin, et al.
Publicado: (2023)

Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
por: Kedor, Claudia, et al.
Publicado: (2021)

Mechanisms, biomarkers and targets for adult-onset Still’s disease
por: Feist, Eugen, et al.
Publicado: (2018)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Automated evaluation of ANA under real-life conditions
por: Loock, Clemens Dario, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
por: Chakraborty, Abhijit, et al.
Publicado: (2012)

Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach
por: Tomaras, Stylianos, et al.
Publicado: (2021)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Safe and effective canakinumab-treatment of neonatal onset multisystem inflammatory disease (NOMID)/ chronic infantile neurologic cutaneous and articular (CINCA)
por: Tsinti, M, et al.
Publicado: (2015)

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
por: Burmester, Gerd R, et al.
Publicado: (2010)

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
por: Burmester, Gerd R, et al.
Publicado: (2011)

Was ist gesichert in der Therapie von autoinflammatorischen Fiebererkrankungen?
por: Pankow, Anne, et al.
Publicado: (2021)

Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in the U.S. Real-World Settings
por: Hur, Peter, et al.
Publicado: (2021)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v9s4dlj7gtmf021f2ris8g98on